Scope, Claims, and US Patent 9,439,900 Landscape for Sublingual Buprenorphine/Naloxone Tablet Technology
US Patent 9,439,900 is directed to a sublingual tablet formulation of buprenorphine plus naloxone that is engineered using microparticle separation/placement, plus an embedded weak acid particle phase and a specific buprenorphine:naloxone dosing ratio. The claims are framed to cover both composition (core ingredients and ratios) and manufacturing-relevant morphology (particle size ranges, “separate from” wording, surface placement, and tablet mechanical strength).
What does claim scope cover at the product level?
The independent claim requires all of the following, in a sublingual tablet:
- Buprenorphine (or pharmaceutically acceptable salt), provided as microparticles
- A weak acid, provided as particles, where the acid particles are separate from the buprenorphine microparticles
- A disintegrant
- Naloxone (or salt), included in the tablet
- Dose constraints per tablet
- Buprenorphine (free base basis) is one of: 11.4 mg, 8.6 mg, 5.7 mg, 2.9 mg, or 1.4 mg
- Dose ratio constraint
- Buprenorphine:naloxone dose (free base basis) is about 4:1
This creates a tight product definition: a branded or generic product that uses different buprenorphine strengths or materially different buprenorphine:naloxone ratios does not fall within the literal scope unless doctrine-of-equivalents arguments succeed.
How broad is the “separate particles” concept?
The wording in claim 1 is explicit that the weak acid particles are separate from the buprenorphine microparticles. Dependent claims then broaden positional embodiments through “associative admixture” and “in contact” formulations:
- Claim 16: microparticles of buprenorphine in associative admixture with weak-acid particles
- Claim 17: microparticles of buprenorphine in contact with weak-acid particles
Practically, the hierarchy indicates the patent’s core concept is not “weak acid as a dissolved excipient,” but weak-acid as a particulate microenvironment that controls properties at the solid-state or upon wetting in the mouth.
What form factors are claimed for the naloxone and weak acid phases?
The claims call out particulate form for both key non-buprenorphine actives or excipient phases:
- Claim 4: naloxone (or salt) is provided as particles
- Claim 5: buprenorphine microparticles and naloxone particles each have weight-based mean diameter 0.5 µm to 15 µm
- Claim 6: weak acid selection list is defined (citric acid through maleic acid, plus ammonium chloride)
- Claims 3 and 6: weak-acid particles are in particulate form with 0.1 µm to 100 µm mean diameter
This means an infringer using:
- dissolved weak acid, or
- weak acid in a single phase that co-micronizes with buprenorphine microparticles, or
- substantially different particle size distributions
faces a clear literal-scope constraint.
Claim-by-Claim Scope Decomposition (What a competitor must do to fall in)
Independent claim 1
A sublingual tablet comprising:
- Buprenorphine microparticles (or salt)
- Weak acid particles, separate from buprenorphine microparticles
- Disintegrant
- Naloxone (or salt)
- Specific buprenorphine doses per tablet: 11.4, 8.6, 5.7, 2.9, or 1.4 mg (free base)
- Buprenorphine:naloxone ratio about 4:1 (free bases)
Practical claim boundaries
- If a product uses buprenorphine strengths outside the enumerated set, it is outside claim 1.
- If a product uses a ratio materially different than 4:1, it is outside claim 1.
- If the weak acid is not a particulate phase or is not “separate” in the required sense, claim 1 is missed.
Claim 2: Disintegrant identity
Disintegrant must be selected from:
- croscarmellose sodium
- sodium starch glycolate
- crosslinked polyvinylpyrrolidone
- mixtures
This is a real scope limiter. Products using alternatives such as crospovidone or polacrilin potassium are not literally covered.
Claim 3: Disintegrant particle size
Disintegrant is in particulate form with:
- 0.1 µm to 100 µm weight-based mean diameter
This gives an additional morphological requirement beyond “selected from the list.” A formulation using the same disintegrant chemotype but substantially different particulate distribution could avoid literal infringement depending on how “mean diameter” is determined.
Claim 4: Naloxone particle form
Naloxone is as particles (or salt in particle form). This excludes approaches where naloxone is molecularly dispersed or primarily dissolved.
Claim 5: Particle size for both microparticle actives
Buprenorphine microparticles and naloxone particles each must be:
- 0.5 µm to 15 µm weight-based mean diameter
This claim ties both actives into a shared particle-size window. A different milling grade that shifts mean size outside 0.5-15 µm may avoid literal scope.
Claim 6: Weak acid identity
Weak acid must be one of:
- citric, malic, tartaric, fumaric, adipic, succinic, lactic, acetic, oxalic, maleic
- ammonium chloride
- combinations
This is an enumerated list that is narrower than many general “pharmaceutically acceptable weak acids” concepts. Use of non-listed acids can be a carve-out.
Claim 7: Optional alkaline salt of weak acid
Adds:
- an alkaline salt of a weak acid, in particles form
This potentially targets dual-phase buffering: weak acid particles plus a corresponding base salt.
Claim 8: Alkaline salt identity
Alkaline salt comprises salts of:
- citric, malic, tartaric, fumaric, adipic, succinic, lactic, acetic, oxalic, maleic acids
Again, list-limited.
Claim 9: Water-soluble carrier particles
Adds:
- water-soluble carrier particles
Claim 10: Carrier particle size
Carrier particles have:
- 100 µm to 800 µm weight-based mean diameter
This defines the excipient matrix scale and is relevant to disintegration, wetting, and drug presentation.
Claims 11 and 12: Carrier excipient material
Carrier comprises a sugar or sugar alcohol, including specifically:
Claim 13: Buprenorphine surface presentation
Buprenorphine microparticles are presented on surfaces of water-soluble carrier particles.
This is a classic “drug-on-carrier” morphology limitation: if the buprenorphine is instead mixed throughout without surface presentation, claim 13 is missed.
Claim 14: Weak-acid location relative to carrier
Weak-acid particles are presented:
- on surfaces of carrier and/or
- between carrier particles
This defines weak-acid spatial positioning that can matter to dissolution in the mouth.
Claim 15: Tablet crushing strength
Tablet crushing strength:
This is an additional mechanical property claim that can help separate technologies with similar compositions but different compression characteristics.
Claim 16: Associative admixture
Buprenorphine microparticles in associative admixture with weak-acid particles.
This is an alternative morphology to “separate,” depending on how “separate” is construed across the independent/dependent set.
Claim 17: Contact
Microparticles of buprenorphine are in contact with weak-acid particles.
This creates a claim ensemble that covers multiple spatial relationships between drug microparticles and acid particles, tightening the formulation concept beyond one manufacturing arrangement.
Claim 18: Specific exemplar composition
Claims the combination of:
- weak acid: citric acid
- disintegrant: croscarmellose sodium
- plus mannitol, sodium citrate, and microcrystalline cellulose
This functions as a defined “fallback” embodiment if broader claims are challenged.
What the patent is trying to protect (core inventive concept)
Based on the claim architecture, US 9,439,900 is built around three linked levers:
-
Drug particle engineering
- buprenorphine as 0.5-15 µm microparticles
- naloxone as 0.5-15 µm particles
-
Weak-acid particulate microenvironment
- weak acid as particles 0.1-100 µm
- weak acid particles separate from (claim 1) and/or placed for “contact” and “associative admixture” embodiments (claims 16-17), and specifically positioned relative to carrier (claim 14)
-
Dose and ratio lock
- buprenorphine dose enumerations (11.4, 8.6, 5.7, 2.9, 1.4 mg)
- buprenorphine:naloxone at about 4:1
That structure creates a “grid” of infringement requirements: an accused product must match the strength/ratio and also the solid-state architecture.
Competitive design-around map (where challengers typically shift)
The claims are restrictive in ways that invite design-around. Below is the most direct map from claim elements to typical avoidance strategies.
| Claim element |
Direct literal requirement |
Common avoidance vector |
| Buprenorphine strength |
Must be 11.4/8.6/5.7/2.9/1.4 mg (free base) |
Use an alternate approved strength not on the list |
| Buprenorphine:naloxone ratio |
About 4:1 (free base) |
Use a meaningfully different ratio |
| Weak acid phase |
Weak acid is particles, separate from buprenorphine microparticles |
Use weak acid molecularly dispersed or co-micronized with buprenorphine so separation fails |
| Weak acid identity |
Enumerated acids (plus ammonium chloride) |
Switch to non-listed weak acid(s) |
| Buprenorphine and naloxone particle sizes |
0.5-15 µm mean diameters each |
Alter milling to shift mean size outside window |
| Disintegrant type |
Listed excipients only |
Switch disintegrant to an excluded type |
| Carrier size |
100-800 µm mean diameter |
Alter carrier grade distribution |
| Buprenorphine presentation |
On surface of carrier (claim 13) |
Blend without surface presentation |
| Weak-acid placement |
On/in between carrier particles (claim 14) |
Distribute weak acid differently within matrix |
| Tablet mechanical strength |
10-100 N crushing |
Alter compression/engineering to shift range |
US patent landscape implications for sublingual buprenorphine/naloxone tablets
A full landscape requires citation to related US patents, priority chains, and claim sets. That information is not contained in the provided record, so only the scope logic of 9,439,900 can be assessed here.
What can be concluded from the claim set itself is that this patent targets a specific formulation family. As a result, landscape screening for competitors should focus on whether their products or their proffered ANDA formulations employ:
- microparticulate buprenorphine and naloxone, both in the 0.5-15 µm mean window
- a particulate weak acid at 0.1-100 µm and its spatial separation/placement relative to drug microparticles and carrier particles
- an enumerated buprenorphine dose and a ~4:1 free-base ratio
- a listed disintegrant and, where applicable, carrier and positioning constraints
These are the technical “search terms” for competitive patent and product surveillance even before document review.
Key Takeaways
- US 9,439,900 claims a sublingual buprenorphine/naloxone tablet defined by both dose/ratio and solid-state particulate engineering.
- The strongest claim boundaries are the enumerated buprenorphine strengths and the ~4:1 buprenorphine:naloxone ratio, coupled with separate particulate weak acid and specific particle size windows for buprenorphine and naloxone.
- Dependent claims add enforceable limits on disintegrant identity and particle size, weak acid identity, carrier composition and particle size, and positional presentation of actives/acid relative to carrier.
- Design-around most plausibly targets the claim’s “locked” elements: strength/ratio, particle size, phase separation, and excipient selection.
FAQs
1) What is the required buprenorphine dose range under claim 1?
11.4 mg, 8.6 mg, 5.7 mg, 2.9 mg, or 1.4 mg per tablet (free base basis).
2) What buprenorphine:naloxone ratio is required?
About 4:1 (both calculated as free bases).
3) What particle-size window applies to buprenorphine and naloxone particles (claim 5)?
Each must have 0.5 µm to 15 µm weight-based mean diameter.
4) What weak-acid particle size window applies (claim 3)?
Weak acid is in particulate form with 0.1 µm to 100 µm weight-based mean diameter.
5) Which disintegrants are explicitly allowed (claim 2)?
Croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone, or mixtures.
References
[1] User-provided claim text for US Drug Patent 9,439,900 (claims 1-18).
